Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
Want to see BDRX full AI Analyst Report?
BDRX Stock Chart & Stats
$2.33
$0.02(0.46%)
At close: 4:00 PM EST
$2.33
$0.02(0.46%)
Day’s Range― - ―
52-Week Range$2.86 - $66.50
Previous CloseN/A
Volume6.04K
Average Volume (3M)260.97K
Market Cap
$1.39M
Enterprise Value-$6.80M
Total Cash (Recent Filing)$8.52M
Total Debt (Recent Filing)$60.89K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Sep 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-107.25
Shares Outstanding648,314
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.03
Enterprise Value/Market Cap-4.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.97
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$7.66K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthBiodexa’s very low leverage and rising equity/assets provide lasting financial flexibility to fund clinical programs without heavy interest burden. A stronger balance sheet reduces near-term insolvency risk and supports partner negotiations and milestone-focused spend allocation over the next 2–6 months.
Clinical-stage, Focused Pipeline And IPThe strategic refocus on GI oncology anchored by a registrational Phase 3 eRapa trial and strengthened IP (U.S. patent) materially improves the company’s development clarity and regulatory pathway. This specialization increases partnering attractiveness and concentrates resources on higher-value, de‑risked assets over the medium term.
Ability To Secure Grants, Financing And PartnershipsDemonstrated success obtaining non‑dilutive grant funding, a recent $10M financing, an in‑license from Otsuka and academic collaborations shows durable capability to assemble capital and strategic relationships. These funding and partnership channels materially support trial recruitment and program continuity.
Bears Say
No Product Revenue / Pre-commercial ProfileBiodexa remains pre‑commercial with zero reported product revenue across recent years, meaning operating sustainability depends entirely on external capital and milestone receipts. Absence of recurring revenue magnifies execution risk and extends the timeline to self-sustaining cashflows if trials prolong or fail.
Persistent Cash Burn And Negative Free Cash FlowDespite year‑over‑year improvement, continued negative operating and free cash flows reflect ongoing burn to advance trials. This pattern requires recurrent financings or partner deals, increasing dilution risk and compressing runway if clinical expenses or enrollment costs rise over the coming months.
Reliance On External Financing And Capital RestructuringThe company’s historical dependence on equity issuance and recent corporate actions (ADR reverse split and proposed share reorganization) indicate structural funding dependence and market pricing pressure. Such moves signal governance and liquidity challenges and can constrain investor confidence and future financing terms.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $2.86 and its highest was $66.50 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $1.39M.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2026 which is in 86 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Apr 24, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 648,314 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.509%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
34.66% Other Institutional Investors
65.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---